Summary
We're thrilled to share the exciting news of launching our inaugural affiliate in the UK! Our decision to expand into the UK is driven by multiple factors:
Over recent years, we've observed that the UK, despite Brexit, continues to be a highly appealing destination for medical research.
With world-renowned centers of medical innovation like University of Cambridge and University of Oxford, many of our clients are either based in the UK or have significant operations there.
At iliomad Health Data , our mission is to support our clients in the best possible locations, and the UK certainly provides an excellent setting for this.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
Interview Paul Chilo Director of Governance, Risk & Compliance at SOPHiA GENETICS - SOPHiA UNITY
Navigating Privacy Requirements for Clinical Trials Across Jurisdictions: Focus on China
China’s data protection regulations play a crucial role in clinical trials, requiring sponsors and researchers to comply with multiple laws, including the PIPL, GCP-2020, and cross-border data transfer rules. Unlike other jurisdictions, China imposes strict consent requirements, risk assessments, and regulatory filings, making compliance a key factor when selecting trial locations and managing participant data.
